Detalhe da pesquisa
1.
Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
J Hepatol
; 66(4): 711-717, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27965158
2.
Treatment optimization and prediction of HCV clearance in patients with acute HCV infection.
J Hepatol
; 59(2): 221-8, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23587473
3.
Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient-centered program from Italy.
United European Gastroenterol J
; 9(10): 1109-1118, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34697911
4.
Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.
J Hepatol
; 53(6): 1000-5, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20843575
5.
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection.
Hepatology
; 49(2): 358-63, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19072829
6.
Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
PLoS One
; 14(9): e0223287, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31553772
7.
SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
PLoS One
; 14(5): e0215783, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31091254